Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wattanapat Hospital Trang PCLBKK:WPH-R +1.35%81 3-Year EBITDA Growth Rate is 34.50% as of Jun. 2026, which is 252% above its 10-year median of 9.80. GuruFocus rates BKK:WPH-R with a GF Score™ of 81/100 and a GF Value™ of ฿9.50 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 527 Healthcare Providers & Services companies, Wattanapat Hospital Trang PCL ranks better than 81.4% on this metric.
During the past 12 months, Wattanapat Hospital Trang PCL's average EBITDA Per Share Growth Rate was -2.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 34.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 54.30% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 22.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Wattanapat Hospital Trang PCL was 100.80% per year. The lowest was -35.50% per year. And the median was 9.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Wattanapat Hospital Trang PCL 3-Year EBITDA Growth Rate Related Terms
BKK:WPH-R vs HCA, THC, DVA: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Wattanapat Hospital Trang PCL's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wattanapat Hospital Trang PCL 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Wattanapat Hospital Trang PCL's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Wattanapat Hospital Trang PCL's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 34.50% mean?
Wattanapat Hospital Trang PCL (BKK:WPH-R) has a 3-Year EBITDA Growth Rate of 34.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Wattanapat Hospital Trang PCL and its competitors. This is 252% above median its historical median of 9.80. According to the industry distribution chart, Wattanapat Hospital Trang PCL ranks #98 out of 527 companies in the Healthcare Providers & Services industry, placing it in the top 18.6%.
Is Wattanapat Hospital Trang PCL's 3-Year EBITDA Growth Rate too high?
Wattanapat Hospital Trang PCL's current 3-Year EBITDA Growth Rate of 34.50% is 252% above median its 10-year median of 9.80. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. Wattanapat Hospital Trang PCL's value of 34.50% is 238.2% above this industry median. Based on the distribution chart, Wattanapat Hospital Trang PCL ranks #98 out of 527 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Wattanapat Hospital Trang PCL has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Wattanapat Hospital Trang PCL's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Wattanapat Hospital Trang PCL ranks #98 out of 527 companies for 3-Year EBITDA Growth Rate. This places Wattanapat Hospital Trang PCL in the top 19% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 10.20. Wattanapat Hospital Trang PCL's value of 34.50% is 238.2% above this benchmark. While the company's 10-year median is 9.80 vs. the industry median of 10.20, Wattanapat Hospital Trang PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 527 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wattanapat Hospital Trang PCL's current 3-Year EBITDA Growth Rate of 34.50% is 238.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Wattanapat Hospital Trang PCL and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wattanapat Hospital Trang PCL's current 3-Year EBITDA Growth Rate is 34.50%, which is 252% above median its own 10-year median of 9.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wattanapat Hospital Trang PCL stock overvalued right now?
Based on GuruFocus' analysis, Wattanapat Hospital Trang PCL (BKK:WPH-R) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿9.50, compared to a current price of ฿5.83 — trading 38.7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 34.50%, which is 252% above median its 10-year median of 9.80 and 238.2% above the Healthcare Providers & Services industry median of 10.20. Wattanapat Hospital Trang PCL's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Wattanapat Hospital Trang PCL (BKK:WPH-R), the current 3-Year EBITDA Growth Rate is 34.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wattanapat Hospital Trang PCL (BKK:WPH-R) Overvalued in 2026?
Based on GuruFocus' analysis, Wattanapat Hospital Trang PCL stock appears to be undervalued.
The current stock price of ฿5.83 is trading 38.7% below its estimated GF Value™ of ฿9.50.
GuruFocus considers Wattanapat Hospital Trang PCL to be Significantly Undervalued.
Key valuation signals for BKK:WPH-R:
3-Year EBITDA Growth Rate: 34.50% (252% above median its 10-year median of 9.80)
GF Value™: ฿9.50 vs. price of ฿5.83 (38.7% below fair value)
Industry Position: 238.2% above the Healthcare Providers & Services median (#98 of 527)
No single metric tells the full story. See the BKK:WPH-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wattanapat Hospital Trang PCL Ltd is engaged in medical services. Its operations are carried on only in Thailand. The company offers a range of services including Orthopedic Clinic, Neurosurgery Clinic, Neurology and Brain Clinic, Surgical Clinic, Heart Clinic, Internal Medicine Clinic, Obstetrics and Gynecology Clinic, Gastrointestinal and Liver Clinic, Children's Clinic, Eye Clinic, ENT Clinic, Dental Clinic, Dermatology and Beauty Clinic, Health Promotion Center, Other Centers and Clinics.
81GF Score
Get the complete analysis for BKK:WPH-R
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:WPH-R has been successfully added to your 
